Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Octreotide Depot · 1 trial · 4 indications
Objective response rate was defined by RECIST criteria: Partial response (PR) must have ≥ 30% decrease in the sum of longest diameter of all target lesions, from the baseline sum. Complete response (CR) must have disappearance of all target and non-target lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments within 4 weeks. Progression = 20% increase in the sum of longest diameter of all target lesions, from smallest sum of longest diameter of all target lesions recorded at or after baseline; or a new lesion; or progression of non-target lesions.
| Arm | Type | Description |
|---|---|---|
| Everolimus 10 mg | EXPERIMENTAL | Stratum 1 patients who were not receiving regular Octreotide Depot therapy. These patients were to receive everolimus monotherapy at 10 mg/day. Stratum 2 patients who were to receive everolimus 10 mg/day in addition to continuing their entry dose of Octreotide Depot therapy. Patients were instructed to take two 5 mg tablets of everolimus orally with a glass of water, once daily (preferably in the morning). Dosing was strongly recommended to occur at the same time every day. |
| Name | Type | Description |
|---|---|---|
| Everolimus 10 mg | DRUG | Participants took two 5 mg tablets of Everolimus orally with a glass of water, once daily (preferably in the morning) in a fasting state or after no more than a light, fat-free meal. Dosing was to occur at the same time each day. If vomiting occurred, the vomited dose was not to be replaced. |
| Octreotide Depot | DRUG | - |
Inclusion criteria for both strata: * Advanced (unresectable or metastatic) biopsy-proven pancreatic Neuroendocrine tumor (NET) * Confirmed low-grade or intermediate-grade neuroendocrine carcinoma * Objective disease progression by Response Evaluation Criteria in Solid tumors (RECIST) criteria whil...
Octreotide Depot is being studied for use in Islet Cell Carcinoma, a type of pancreatic neuroendocrine tumor. It is an investigational small molecule in Phase 2 clinical development for this indication. The drug is being evaluated in patients with advanced pancreatic neuroendocrine cancer that has not responded to chemotherapy.
Octreotide Depot is a small molecule being developed for oncology. It is being investigated in Islet Cell Carcinoma, a form of pancreatic neuroendocrine cancer. The specific molecular target of Octreotide Depot has not been disclosed in the available clinical trial information.
Octreotide Depot is being developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker NVS. The company is conducting clinical research on this drug for the treatment of Islet Cell Carcinoma.
Octreotide Depot is in Phase 2 clinical development. It is an investigational drug being studied for Islet Cell Carcinoma, a type of pancreatic neuroendocrine tumor. The drug is not yet approved and is still undergoing clinical trials to evaluate its safety and efficacy.
Octreotide Depot is associated with clinical trial NCT00363051, a Phase 2 study titled 'Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy.' This completed trial enrolled 160 participants across multiple countries, including the United States, Argentina, Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, and Sweden.
Octreotide Depot is not the same as Everolimus. The clinical trial NCT00363051, which evaluates Everolimus, is the trial associated with Octreotide Depot's development program. However, Octreotide Depot is a distinct drug being developed by Novartis AG for Islet Cell Carcinoma.